Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$119.41 USD

119.41
10,465,017

+9.13 (8.28%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $119.37 -0.04 (-0.03%) 7:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (142 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Zacks Equity Research

The Zacks Analyst Blog Highlights Moderna, Gilead Sciences, Kodiak Sciences and Lexicon Pharmaceuticals

by Zacks Equity Research

Moderna, Gilead Sciences, Kodiak Sciences and Lexicon Pharmaceuticals have been highlighted in this Analyst Blog.

Zacks Equity Research

Biotech Stock Roundup: MRNA's Q4 Earnings, LXRX, KOD Down on Updates & More

by Zacks Equity Research

Updates from Moderna (MRNA) and Kodiak Sciences Inc (KOD) are a few key highlights from the biotech sector during the past week.

Zacks Equity Research

Gilead (GILD) Down 7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Zacks Equity Research

VIR Q4 Earnings Beat on Higher Revenues From Covid Treatment

by Zacks Equity Research

VIR beat earnings estimates in the fourth quarter on higher sotrovimab revenues for COVID-19 patients.

Zacks Equity Research

Ligand (LGND) Q4 Earnings Beat, OmniAb Spin-Off in 1H22

by Zacks Equity Research

Ligand (LGND) reports encouraging fourth-quarter 2021 numbers by beating estimates on both counts. However, royalties decline. The company plans to complete business separation in the first half of 2022.

Zacks Equity Research

Biotech Stock Roundup: BDSI Surges on Merger Deal, SGEN Down on Outlook & More

by Zacks Equity Research

Merger updates from BioDelivery (BDSI) and Seagen (SGEN) earnings results are among a few key highlights from the biotech sector during the past week.

Zacks Equity Research

Gilead (GILD) Veklury Retains Activity Against Omicron Variant

by Zacks Equity Research

Gilead's (GILD) Veklury (remdesivir) retains antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants in multiple in vitro studies.

Sweta Jaiswal, FRM headshot

How Are Biotech ETFs Reacting to These Q4 Earnings Releases?

by Sweta Jaiswal, FRM

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Zacks Equity Research

Biotech Stock Roundup: GILD Q4 Earnings, REGN, MRNA's Regulatory Updates & More

by Zacks Equity Research

Earnings updates from Gilead (GILD) and regulatory updates are among a few key highlights from the biotech sector during the past week.

Zacks Equity Research

Gilead (GILD) Q4 Earnings Miss on Legal Settlement Charges

by Zacks Equity Research

Gilead (GILD) misses on earnings but beats on sales in the fourth quarter. While the HIV business maintains momentum on Biktarvy, sales of Veklury decline.

Zacks Equity Research

Gilead Sciences (GILD) Q4 Earnings Miss Estimates

by Zacks Equity Research

Gilead (GILD) delivered earnings and revenue surprises of -54.90% and 9.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

Big Data for Q4, Econ to Start a New Month

by Mark Vickery

We've got a big day ahead with both economic prints and Q4 earnings reports.

Zacks Equity Research

Wall Street Waits for Major Economic Data This Week

by Zacks Equity Research

Wall Street Waits for Major Economic Data This Week.

Zacks Equity Research

Should Value Investors Pick Gilead Sciences (GILD) Stock?

by Zacks Equity Research

Is Gilead Sciences (GILD) a great pick from the value investor's perspective right now? Read on to know more.

Zacks Equity Research

Should You Buy Gilead Sciences (GILD) Ahead of Earnings?

by Zacks Equity Research

Gilead Sciences (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Pfizer (PFE) Gets CHMP Recommendation for COVID Pill Paxlovid

by Zacks Equity Research

Pfizer's (PFE) oral COVID-19 drug, Paxlovid, gets recommendation from the CHMP for its authorization in Europe for treating mild-to-moderate COVID-19 in patients at increased risk of hospitalizations.

Zacks Equity Research

Gilead (GILD) to Report Q4 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) fourth-quarter 2021 results.

Nalak Das headshot

5 Corporate Giants Likely to Gain From Q4 Earnings Next Week

by Nalak Das

Five corporate behemoths will report fourth-quarter 2021 earnings results next week. These are: TMO, FB, GOOGL, GILD and UPS.

Zacks Equity Research

Biotech Stock Roundup: VRTX Q4 Earnings, GILD, INCYs Regulatory Updates & More

by Zacks Equity Research

Earnings updates from Vertex (VRTX) and pipeline updates are among a few key highlights from the biotech sector during the past week.

Zacks Equity Research

Gilead's (GILD) Magrolimab Studies Put on Hold by the FDA

by Zacks Equity Research

Gilead (GILD) efforts to build an oncology franchise get jolted as the FDA places hold on a few studies evaluating the combination of magrolimab plus azacitidine.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, Merck, Eli Lilly, Regeneron and Gilead

by Zacks Equity Research

Pfizer, Merck, Eli Lilly, Regeneron and Gilead are included in this analyst blog.

Zacks Equity Research

Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Large Cap Pharma, Biotech Stocks Down on Regulatory Updates

by Zacks Equity Research

Pharma giants like Pfizer (PFE), Merck (MRK) and Eli Lilly (LLY), along with biotech bigwig Regeneron (REGN), are down on regulatory updates.